医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Kamiyacho Neurosurgical Clinic in Japan Celebrates First Brain Tumor Patient Treated with the New ZAP-X® Gyroscopic Radiosurgery® Platform

2023年10月24日 PM06:00
このエントリーをはてなブックマークに追加


 

SAN CARLOS, Calif.

ZAP Surgical, a leading innovator in the field of surgical robotics, today announced the first patient treatment using the groundbreaking ZAP-X® Gyroscopic Radiosurgery® platform at Kamiyacho Neurosurgical Clinic in Tokyo, Japan. The event took place on October 19th, marking a significant milestone in the field of neurosurgical care and cancer treatment. Kamiyacho Neurosurgical Clinic, located on the 2nd floor of the Tokyo World Gate Tower, is the second healthcare facility in Japan to introduce the ZAP-X platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231019369649/en/

The front reception at Kamiyacho Neurosurgical Clinic, showcasing the ZAP-X platform with floor to ceiling windows. (Photo: Business Wire)

The front reception at Kamiyacho Neurosurgical Clinic, showcasing the ZAP-X platform with floor to ceiling windows. (Photo: Business Wire)

The Tokyo World Gate Tower, situated in the vibrant business district of Tokyo, offers an added layer of convenience for patients, not only in the city but for those from all over Japan. The tower’s strategic location is directly connected to the subway station and houses various hotels and company offices.

As a completely non-invasive outpatient treatment for select brain tumors and other cranial indications, stereotactic radiosurgery (SRS) is a proven alternative to historical surgical procedures. Unlike surgery, however, the SRS procedure requires no incisions and is painless. In most cases, patients immediately return to normal activities following SRS.

The ZAP-X system stands out with its innovative design, employing distinct gyroscopic mobility to guide radiosurgical beams from hundreds of unique angles, and ensuring precise radiation concentration on the tumor target. This innovative method aligns with the clinical goal of safeguarding the patient’s healthy brain tissue and maintaining cognitive function.

Additionally, the vault-free ZAP-X system is well-known for its ability to eliminate the high costs associated with constructing shielded radiation treatment rooms. This self-shielding feature successfully cleared the rigorous Japanese nuclear regulations, which are known to be among the most stringent in the world. The ZAP-X also eliminates the necessity of managing, securing, and frequently replacing live radioactive isotopes used in historical radiation beam production.

Combined, these ZAP-X innovations allow for newfound siting flexibility, and consequently bring world-class SRS to locations previously considered infeasible.

Dr. Ryutaro Nomura, Neurosurgeon and Director of Kamiyacho Neurosurgical Clinic, expressed his enthusiasm, stating, “It is impossible to install other radiosurgery devices into such a small clinic in an office building in the Tokyo city center. The ZAP-X’s compact and innovative design has made it possible for us to bring state-of-the-art radiosurgery treatment to our patients in this unique urban outpatient setting.”

Eight additional patients are already booked for ZAP-X treatment later in October, underscoring the clinic’s commitment to offering cutting-edge care to patients across Japan.

About ZAP Surgical Systems, Inc.

ZAP Surgical Systems, Inc. designs and manufactures the ZAP-X® Gyroscopic Radiosurgery® platform. ZAP was founded in 2014 by Dr. John R. Adler. In addition to being CEO of ZAP, Dr. Adler is Emeritus Dorothy & TK Chan Professor of Neurosurgery and Radiation Oncology at Stanford University. Dr. Adler is also renowned as the inventor of the CyberKnife® system and founder of Accuray, Inc. The ZAP-X platform incorporates a unique vault-free design that typically eliminates the need for costly shielded treatment rooms. ZAP-X also utilizes a modern linear accelerator to eliminate legacy use of Cobalt-60. Learn more at ZAP Surgical and follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231019369649/en/

CONTACT

Mark Arnold, ZAP Surgical Systems, Inc.

Senior Vice President, Marketing

+1 650 492 7797, ext. 101

Email: info@zapsurgical.com

同じカテゴリーの記事 

  • Poxel Provides a Financial Update for the First Quarter 2024 and Announces the Postponement of its 2023 Full-Year Results Release
  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)